Browse > Article
http://dx.doi.org/10.14776/piv.2017.24.3.125

Evaluation of Antibodies Against Haemophilus influenzae Type b in Korean Adults  

Lee, Ji Hyen (Department of Pediatrics, Ewha Womans University School of Medicine)
Kim, Han Wool (Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine)
Lee, Soyoung (Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine)
Kim, Kyung-Hyo (Department of Pediatrics, Ewha Womans University School of Medicine)
Publication Information
Pediatric Infection and Vaccine / v.24, no.3, 2017 , pp. 125-133 More about this Journal
Abstract
Purpose: After the introduction of Haemophilus influenzae type b (Hib) vaccine in 1995 in Korea, it was included in the national immunization program in 2013. In the post-Hib vaccine era, some studies in other countries reported that invasive Hib disease affects adults, especially the elderly and immunocompromised persons, more often than it affects children. To evaluate disease susceptibility, quantitative and qualitative analysis of anti-polyribosylribitol phosphate (PRP) antibodies were carried out in Korean adults aged 20 to 85 years. Methods: Sera were collected from 39 healthy adults (20 to 50 years of age) and from 30 elderly adults (75 to 85 years of age) who did not have immune-compromising conditions. The concentration of anti-PRP immunoglobulin G (IgG) and serum bactericidal indices (SBIs) were measured by enzyme-linked immunosorbent assay and serum bactericidal assay. Results: Geometric mean concentrations of anti-PRP IgG and geometric mean SBIs were $0.88{\mu}g/mL$ (95% confidence interval [CI], 0.17 to 3.85) and 354 (95% CI, 50 to 2,499) in young adults and $1.67{\mu}g/mL$ (95% CI, 0.53 to 5.24) and 449 (95% CI, 146 to 1,376) in elderly adults, respectively. When the threshold of seropositivity for anti-PRP IgG was applied as 0.15 or $1.0{\mu}g/mL$, which is the protective antibody level in children, seropositive rates were 87.2% or 53.8% in young adults and 100% or 60% in elderly adults. The seropositivity rates of the SBI ($SBI{\geq}4$) were 82.1% and 100% in the groups, respectively. Conclusions: Most subjects in the adult and elderly adult groups display immunity to Hib based on quantitative and qualitative antibody levels, but not all. Because high immunization and low Hib circulation rates may reduce the natural Hib immunity in the population, monitoring Hib immunity as well as disease are needed continuously.
Keywords
Haemophilus influenzae type b; Antibodies; Adult; Aged;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Idoko OT, Roberts E, Cox M, Jafali J, Njie-Jobe J, Mackenzie G, et al. Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups. Vaccine 2014;32:4620-4.   DOI
2 McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004;329: 655-8.   DOI
3 Dworkin MS, Park L, Borchardt SM. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons > or = 65 years old. Clin Infect Dis 2007;44:810-6.   DOI
4 Rubach MP, Bender JM, Mottice S, Hanson K, Weng HY, Korgenski K, et al. Increasing incidence of invasive Haemophilus influenzae disease in adults, Utah, USA. Emerg Infect Dis 2011;17:1645-50.   DOI
5 Shuel M, Hoang L, Law DK, Tsang R. Invasive Haemophilus influenzae in British Columbia: non-Hib and nontypeable strains causing disease in children and adults. Int J Infect Dis 2011;15:e167-73.   DOI
6 Kim KH, Lim SY. Validation of enzyme immunoassay for the quantitative measurement of human IgG antibodies specific for Haemophilus influenzae type b capsular poly saccharide. Korean J Pediatr 2007;50:143-50.   DOI
7 Kim HW, Kim KH, Kim J, Nahm MH. A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b. BMC Infect Dis 2016;16:473.   DOI
8 Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977;60: 730-7.
9 Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier Health Sciences, 2013:167-82.
10 Pittman M. Variation and type specificity in the bacterial species Hemophilus influenzae. J Exp Med 1931;53:471-92.   DOI
11 Kim KH, Lee H, Chung EH, Kang JH, Kim JH, Kim JS, et al. Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants. J Korean Med Sci 2008;23:929-36.   DOI
12 Chalmers C. Necrotising fasciitis complicating Haemophilus influenzae type b epiglottitis in an adult. J Laryngol Otol 2010;124:807-9.   DOI
13 Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy N, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008;197:1275-81.   DOI
14 Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.   DOI
15 Nix EB, Hawdon N, Gravelle S, Biman B, Brigden M, Malik S, et al. Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era. Clin Vaccine Immunol 2012;19:766-71.   DOI
16 Saito T, Matsunaga H, Matsumura Y, Segawa H, Takakura S, Nagao M, et al. Necrotizing fasciitis caused by Haemophilus influenzae type b in an elderly patient. J Clin Microbiol 2009;47:852-4.   DOI
17 Chew CG, Clarkson AR, Faull RJ. Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae. Nephrol Dial Transplant 1997;12:821-2.   DOI
18 Neuhaus TJ, Iselin H, Nadal D. Haemophilus influenzae: a cause of peritonitis in peritoneal dialysis. Nephrol Dial Transplant 1996;11:199-200.   DOI
19 Public Health Agency of Canada. Canadian immunization guide 2006. 7th ed. Ottawa: Public Health Agency of Canada, 2006.
20 Collins S, Ramsay M, Campbell H, Slack MP, Ladhani SN. Invasive Haemophilus influenzae type b disease in England and Wales: who is at risk after 2 decades of routine childhood vaccination? Clin Infect Dis 2013;57:1715-21.   DOI
21 World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. Proposed revision of WHO TRS 924, Annex 1 [Internet]. Geneva: World Health Organization; 2004 [cited 2017 Nov 7]. Available from: http://www.who.int/biologicals/BS2287_Clinical_guidelines_final_LINE_NOs_20_July_2016.pdf.
22 Mackenzie GA, Ikumapayi UN, Scott S, Idoko O, Odutola A, Ndiaye M, et al. Increased disease due to Haemophilus influenzae type b: population-based surveillance in eastern Gambia, 2008-2013. Pediatr Infect Dis J 2015;34:e107-12.   DOI
23 Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009;49:85-92.   DOI
24 Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis 2005;41:839-47.   DOI
25 Jelonek MT, Chang SJ, Chiu CY, Park MK, Nahm MH, Ward JI. Comparison of naturally acquired and vaccineinduced antibodies to Haemophilus influenzae type b capsular polysaccharide. Infect Immun 1993;61:5345-50.
26 Kim YJ, Hwang JY, Choi SH, Kong E, Kim Y, Park KS, et al. Antibody responses in hematopoietic cell transplantation recipients after vaccination against Haemophilus influenzae type b and Streptococcus pneumoniae. Korean J Pediatr Infect Dis 2014;21:81-95.   DOI
27 Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009;16:376-81.   DOI
28 Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 2013;19:412-25.   DOI
29 Cho HK, Park IH, Burton RL, Kim KH. Impact of IgM antibodies on cross-protection against pneumococcal serogroups 6 and 19 after immunization with 7-valent pneumococcal conjugate vaccine in children. J Korean Med Sci 2016;31:950-6.   DOI
30 Kim KH. Present status and prospects of Haemophilus influenzae type b (Hib) immunization. Korean J Pediatr 2006;49:242-50.   DOI
31 Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003;143(6 Suppl):S163-87.
32 Shinefield HR, Black S. Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up. Pediatr Infect Dis J 1995;14:978-81.   DOI